Sinusitis, Acute, Medical Treatment
- Author: Steven E Sobol, MD, FRCSC, MSc, FAAP; Chief Editor: Arlen D Meyers, MD, MBA more...
Background
Many classifications, both clinical and radiological, have been proposed in the literature to define acute sinusitis. Although no consensus on the precise definition currently exists, acute sinusitis may be defined as a bacterial or viral infection of the sinuses of fewer than 4 weeks duration that resolves completely with appropriate treatment. Subacute sinusitis represents a temporal progression of symptoms for 4-12 weeks. Recurrent acute sinusitis is diagnosed when 2-4 episodes of infection occur per year with at least 8 weeks between episodes, and, as in acute sinusitis, the sinus mucosa completely normalizes between attacks. Chronic sinusitis is the persistence of insidious symptomatology beyond 12 weeks, with or without acute exacerbations, and is discussed in Sinusitis, Chronic, Medical Treatment.
Air-fluid level (arrow) in the maxillary sinus suggests sinusitis. Embryology
To properly diagnose and treat infectious disorders of the paranasal sinuses, the clinician should have knowledge of the developmental milestones. The development of the paranasal sinuses begins in the third week of gestation and continues until early adulthood.
During the third week of embryonic development, proliferation and medial migration of ectodermal cells form the notochord. After the heart tube and pericardium have rotated from the cranial position to lie anteriorly, the notochord, which is initially in the caudal region of the embryonic disc, rotates to lie posterior to the primitive foregut. The paraxial layer of mesenchyme, which lies adjacent to the notochord, differentiates into the somite ridges, intermediate cell mass, and lateral plate mesoderm. From these mesodermal structures the branchial arches develop, the first of which gives rise to internal nasal structures.
The paranasal sinuses develop in conjunction with the palate from changes in the lateral wall of the nasal cavity. At 40 weeks' gestation, 2 horizontal grooves develop in the mesenchyme of the lateral wall of the nasal cavity. Proliferation of maxilloturbinate mesenchyme between these grooves results in an outpouching of tissue medially into the nasal lumen. This outpouching is the precursor of the middle and inferior meatus as well as the inferior turbinate. Ethmoidoturbinate folds develop superiorly to give rise to the middle and superior turbinates. Once the turbinate structures are established, sinus development begins and continues until early adult life.
Anatomy
The paranasal sinuses are air-filled bony cavities that extend from the skull base to the alveolar process and laterally from the nasal cavity to the inferomedial aspect of the orbit and the zygoma. They are lined with pseudostratified columnar epithelium that is contiguous, via ostia, with the lining of the nasal cavity. This epithelium contains a number of mucous-producing goblet cells. The arterial supply of the paranasal sinuses is from branches of the internal and external carotid arteries, while the venous and lymphatic drainage path is through the sinus ostia into the nasal cavity plexus. In addition, venous drainage occurs through valveless vessels corresponding to the arterial supply. The focal point of sinus drainage is the ostiomeatal complex, which is located in the middle meatus and is composed of the maxillary, frontal, and anterior ethmoid ostia. The posterior ethmoids empty into the superior meatus, and the sphenoids empty into the sphenoethmoidal recess.
The exact function of the paranasal sinuses is not well understood. The possible roles of the sinuses may include reducing the weight of the skull; dampening pressure; humidifying and warming inspired air; absorbing heat and insulating the brain; aiding in sound resonance; providing mechanical rigidity; and increasing the olfactory surface area.
The sinus mucosa has less secretory and vasomotor function than the nasal cavity does. Cilia are concentrated near and beat toward the natural sinus ostia. Blockage of the ostium results in stasis of mucous flow, which can lead to development of disease.
Pathophysiology
The sinuses are normally sterile under physiologic conditions. Purulent sinusitis can occur when ciliary clearance of sinus secretions decreases or when the sinus ostium becomes obstructed, which leads to retention of secretions, negative sinus pressure, and reduction of oxygen partial pressure. This environment is then suitable for growth of pathogenic organisms. Factors that predispose the sinuses to obstruction and decreased ciliary function are allergic, nonallergic, or viral insults, which produce inflammation of the nasal and sinus mucosa and result in ciliary dysmotility and sinus obstruction. Approximately 90% of patients who have viral upper respiratory tract infections (URTIs) have sinus involvement, but only 5-10% of these patients have bacterial superinfection requiring antimicrobial treatment.
Anatomical variations that narrow the ostiomeatal complex, including septal deviation, paradoxical middle turbinates, and Haller cells, make this area more sensitive to obstruction from mucosal inflammation. Mechanical obstruction of the ostiomeatal complex from foreign bodies, polyps, or tumors can also result in acute sinus disease. Systemic diseases that result in decreased mucociliary clearance, including cystic fibrosis and Kartagener syndrome, can be predisposing factors for acute sinusitis in rare cases. Patients with immunodeficiencies (eg, agammaglobulinemia, combined variable immunodeficiency, and immunodeficiency with reduced immunoglobulin G [IgG]– and immunoglobulin A [IgA]–bearing cells) are also at increased risk of developing acute sinusitis.
Acute sinusitis in the intensive care population is a distinct entity, occurring in 18-32% of patients with prolonged periods of intubation, and is usually diagnosed during the evaluation of unexplained fever. Cases in which the cause is obstruction are usually evident and can include the presence of prolonged nasogastric or nasotracheal intubation. Moreover, patients in an intensive care setting are generally debilitated, predisposing them to septic complications, including sinusitis.
Ciliary function is also reduced in the presence of low pH, anoxia, bacterial toxins, smoking, dehydration, foreign bodies, and drugs (eg, atropine, antihistamines, phenylephedrine). Approximately 10% of cases of acute sinusitis result from direct inoculation of the sinus with a large amount of bacteria. Dental abscesses or procedures that result in communication between the oral cavity and sinus can produce sinusitis by this mechanism. Facial trauma or large inoculations from swimming can produce sinusitis as well.
Epidemiology
Frequency
United States
Sinusitis affects 1 out of every 7 adults in the United States, with over 30 million individuals diagnosed each year. Acute bacterial sinusitis is the fifth most common diagnosis prompting antibiotic administration and accounts for 0.4% of ambulatory diagnoses.[1] The economic burden of acute sinusitis in children is $1.77 billion per year.[2]
Bishai WR. Issues in the management of bacterial sinusitis. Otolaryngol Head Neck Surg. Dec 2002;127(6 Suppl):S3-9. [Medline].
Ray NF, Baraniuk JN, Thamer M, Rinehart CS, Gergen PJ, Kaliner M. Healthcare expenditures for sinusitis in 1996: contributions of asthma, rhinitis, and other airway disorders. J Allergy Clin Immunol. Mar 1999;103(3 Pt 1):408-14. [Medline].
[Guideline] Rosenfeld RM, Andes D, Bhattacharyya N, Cheung D, Eisenberg S, Ganiats TG, et al. Clinical practice guideline: adult sinusitis. Otolaryngol Head Neck Surg. Sep 2007;137(3 Suppl):S1-31. [Medline].
Savolainen S, Jousimies-Somer H, Karjalainen J. Do simple laboratory tests help in etiologic diagnosis in acute maxillary sinusitis?. Acta Otolaryngol Suppl. 1997;529:144-7. [Medline].
Slack CL, Dahn KA, Abzug MJ, Chan KH. Antibiotic-resistant bacteria in pediatric chronic sinusitis. Pediatr Infect Dis J. Mar 2001;20(3):247-50. [Medline].
Sobol SE, Marchand J, Tewfik TL, Manoukian JJ, Schloss MD. Orbital complications of sinusitis in children. J Otolaryngol. Jun 2002;31(3):131-6. [Medline].
Chandler JR, Langenbrunner DJ, Stevens ER. The pathogenesis of orbital complications in acute sinusitis. Laryngoscope. Sep 1970;80(9):1414-28. [Medline].
[Guideline] Slavin RG, Spector SL, Bernstein IL, Kaliner MA, Kennedy DW, Virant FS, et al. The diagnosis and management of sinusitis: a practice parameter update. J Allergy Clin Immunol. Dec 2005;116(6 Suppl):S13-47. [Medline].
AHCPR Evidence Report. Agency for Health Care Policy and Research. In: Diagnosis and treatment of acute bacterial rhinosinusitis. Rockville, MD. 1999.
Brook I, Gooch WM III, Jenkins SG. Medical Management of acute bacterial sinusitis. Recommendations of a clinical advisory committee on pediatric and adult sinusitis. Ann Otol Rhinol Laryngol. 2000;109(Suppl):2-20.
Conrad DA, Jenson HB. Management of acute bacterial rhinosinusitis. Curr Opin Pediatr. 2002;14(1):86-90.
Eibling DE. Maxillary Sinus: Irrigation Techniques. In: Myers EN, ed. Operative Otolaryngology-Head and Neck Surgery. Philadelphia, Pa: WB Saunders; 1997:81-85.
Frenkiel S. Embryology of the Nose and Sinuses. In: Tewfik TL, Der Kaloustian VM, eds. Congenital Anomalies of the Ear, Nose, and Throat. New York: Oxford University Press; 1997:183-187.
Graney DO, Rice DH. Anatomy. In: Cummings CW, Frederickson JM, Harker LA, Krause CJ, Richardson MA, Schuller DE, eds. Otolaryngology-Head & Neck Surgery. 3rd ed. St. Louis: Mosby; 1998:1059-1064.
International Rhinosinusitis Advisory Board. Infectious rhinosinusitis in adults: classification, etiology and management. International Rhinosinusitis Advisory Board. Ear Nose Throat J. Dec 1997;76(12 Suppl):1-22. [Medline].
Johnson JT, Ferguson BJ. Infection. In: Cummings CW, Frederickson JM, Harker LA, Krause CJ, Richardson MA, Schuller DE, eds. Otolaryngology-Head & Neck Surgery. 3rd ed. St. Louis: Mosby; 1998:1107-1118.
Josephson GD, Gross CW. Diagnosis & management of acute & chronic sinusitis. Compr Ther. Nov 1997;23(11):708-14. [Medline].
Kaliner MA, Osguthorpe JD, Fireman P. Sinusitis: bench to bedside. Current findings, future directions. Otolaryngol Head Neck Surg. Jun 1997;116(6 Pt 2):S1-20. [Medline].
Laine K, Maatta T, Varonen H. Diagnosing acute maxillary sinusitis in primary care: a comparison of ultrasound, clinical examination and radiography. Rhinology. Mar 1998;36(1):2-6. [Medline].
Low DE, Desrosiers M, McSherry J. A practical guide for the diagnosis and treatment of acute sinusitis. CMAJ. Mar 15 1997;156 Suppl 6:S1-14. [Medline].
Manning SC. Medical Management of Infectious and Inflammatory Disease. In: Cummings CW, Frederickson JM, Harker LA, Krause CJ, Richardson MA, Schuller DE, eds. Otolaryngology-Head & Neck Surgery. 3rd ed. St. Louis: Mosby; 1998:1135-1144.
McCaig LF, Hughes JM. Trends in antimicrobial drug prescribing among office-based physicians in the United States. JAMA. Jan 18 1995;273(3):214-9. [Medline].
Poole MD. A focus on acute sinusitis in adults: changes in disease management. Am J Med. May 3 1999;106(5A):38S-47S; discussion 48S-52S. [Medline].
Rhys-Evans PH. Anatomy of the Nose and Paranasal Sinuses. In: Kerr AG, Groves J, eds. Scott-Brown's Otolaryngology. 5th ed. London: Butterworths; 1987:138-161.
Talmor M, Li P, Barie PS. Acute paranasal sinusitis in critically ill patients: guidelines for prevention, diagnosis, and treatment. Clin Infect Dis. Dec 1997;25(6):1441-6. [Medline].
Taylor JA, Weber W, Standish L, et al. Efficacy and safety of echinacea in treating upper respiratory tract infections in children: a randomized controlled trial. JAMA. Dec 3 2003;290(21):2824-30. [Medline].
Wald ER. Expanded role of group A streptococci in children with upper respiratory infections. Pediatr Infect Dis J. Aug 1999;18(8):663-5. [Medline].
Wald ER. Microbiology of acute and chronic sinusitis in children and adults. Am J Med Sci. Jul 1998;316(1):13-20. [Medline].
Wald ER. Sinusitis. Pediatr Ann. Dec 1998;27(12):811-8. [Medline].
Westergren V. Artificial ventilation-acquired sinopathy in the critically ill - the maxillary sinuses revisited. Clin Exp Allergy. Mar 1999;29(3):298-305. [Medline].
| Antibiotic | Dosage | Streptococcus pneumoniae | Haemophilus influenzae | Moraxella catarrhalis | Anaerobic bacteria | ||
| Sensitive | Intermediate | Resistant | |||||
| Amoxicillin | 500 mg PO tid | +++ | ++ | + | ++ | + | + |
| Clarithromycin | 250-500 mg PO bid | ++ | ++ | + | ++ | +++ | + |
| Azithromycin | 500 mg PO first day, then 250 mg/d PO for 4 days | ++ | ++ | + | ++ | +++ | + |
| Antibiotic | Dosage | Streptococcus pneumoniae | Haemophilus influenzae | Moraxella catarrhalis | Anaerobic bacteria | ||
| Sensitive | Intermediate | Resistant | |||||
| Amoxicillin/clavulanate | 500 mg PO tid | +++ | ++ | + | +++ | +++ | +++ |
| Cefuroxime | 250-500 mg PO bid | +++ | ++ | + | +++ | ++ | ++ |
| Cefpodoxime + cefixime | 200 mg PO bid 400 mg/d PO | - ++ | +++ - | ++ - | + +++ | +++ +++ | +++ - |
| Ciprofloxacin | 500-750 mg PO bid | ++ | + | + | ++ | +++ | + |
| Levofloxacin | 500 mg/d PO | +++ | +++ | +++ | +++ | +++ | +++ |
| Trovafloxacin | 200 mg/d PO | +++ | +++ | +++ | +++ | +++ | +++ |
| Clindamycin | 300 mg PO tid | +++ | +++ | +++ | - | - | +++ |
| Metronidazole | 500 mg PO tid | - | - | - | - | - | +++ |
| Antibiotic | Dosage | Streptococcus pneumoniae | Haemophilus influenzae | Moraxella catarrhalis | Gram-negative | Anaerobic bacteria |
| Piperacillin | 3-4 g IV q4-6h | +++ | + | - | +++ | +++ |
| Piperacillin/tazobactam | 3.375 g IV q6h | +++ | +++ | +++ | +++ | ++ |
| Ticarcillin | 3 g IV q4h | +++ | - | - | +++ | ++ |
| Ticarcillin/clavulanate | 3.1 g IV q4h | +++ | +++ | - | +++ | ++ |
| Imipenem | 500 mg IV q6h | +++ | +++ | +++ | +++ | +++ |
| Meropenem | 1 g IV q8h | +++ | +++ | +++ | +++ | ++ |
| Cefuroxime | 1 g IV q8h | +++ | +++ | +++ | ++ | ++ |
| Ceftriaxone | 2 g IV bid | +++ | +++ | +++ | +++ | ++ |
| Cefotaxime | 2 g IV q4-6h | +++ | +++ | +++ | +++ | ++ |
| Ceftazidime | 2 g IV q8h | +++ | +++ | +++ | +++ | ++ |
| Gentamicin | 1.7 mg/kg IV q8h | - | +++ | +++ | ++ | - |
| Tobramycin | 1.7 mg/kg IV q8h | - | +++ | +++ | ++ | - |
| Vancomycin | 1 g IV q6-12h | +++ | - | - | - | ++ |

